Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹787.55down ₹5.45 (0.69%)BSE ₹787.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹793.00.
29 Oct: open ₹793.00, high ₹799.45, low ₹785.90
52-week range of traded prices to 29 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,449 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,66353.4% delivered
Natco Pharma orders, deals and press releases
241 filed, newest first. Page 5 of 5.
Jul 2013
May 2013
Feb 2013
Dec 2012
Nov 2012
Aug 2012
Jun 2012
May 2012
Apr 2012
17 Apr · Business
Mar 2012
Feb 2012
Dec 2011
Nov 2011
Oct 2011
Aug 2011
Jun 2011
May 2011
31 May · Business
Mar 2011
Feb 2011
Jan 2011
14 Jan · Business
Dec 2010
Nov 2010
Oct 2010
Aug 2010
Jun 2010
Jan 2010
27 Jan · Business
Press release dated January 27, 2010, which is as follows: "Hyderabad based NATCO Pharma Limited had recommended a payment of Rs.2 per equity share as an interim dividend for the financial year 2009-10. The Board of Directors, which met at Hyderabad today noted, that the company has recorded a 11% growth in revenues on a year-on-year on basis (at Rs.83 Crores in the third quarter of the current fiscal as against Rs.75 Crores in the last year). The net profit, after tax, on a stand-alone basis has also gone up by 7% on a year-on-year basis (from Rs.1128 lakhs to Rs.1209 lakhs) in the third quarter of the current year. On a consolidated basis, the cumulative earnings up to end of December, 2009 amounted to Rs.349 Crores (as against Rs.331 Crores last year), while the cumulative profit after tax stood at Rs.3368 lakhs (as against Rs.3271 lakhs last year)".
Apr 2009
15 Apr · Business
Press release dated April 15, 2009, titled "NATCO ties up with Dr. Reddy's for oncological products". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Apr · Business
Press release dated April 09, 2009, titled "NATCO joins hands with LUPIN to commercialize Lanthanum Carbonate tablets, possibility of being first filers". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
16 Mar · Business
Press release dated March 16, 2009, titled "NATCO Successfully Opposes Indian Patent Application Covering Composition of Teva's Copaxone(R) Multiple Sclerosis Treatment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Business
Press release dated Janaury 27, 2009, titled "Natco's Q3 results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
19 Sep · Business
Press release dated September 19, 2008, titled "Natco makes a debut in nano-technology, launches Albupax". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
31 Jul · Business
Press release dated July 31, 2008, titled "Natco's Q1 results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
16 May · Business
Press release, dated May 16, 2007, titled "NATCO fortifies its presence in Neurology segment, launches Glatimer." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
12 Mar · Business
Press release, dated March 12, 2007, titled "NATCO announces drug donation program". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.